4[1]O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 months[J]. Circulation, 1997;95(5):1126-31
5[2]Osamah H, Mira R, Sorina S, Shlomo K, Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets [J]. Br J Clin Pharmacol, 1997;44(1):77- 83
6[3]Ridker PM, Rifai N, Marc A, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators[ J]. Circulation, 1999; 100(3): 230 - 5
7[4]Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A,Plaza JJ, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture[J]. Circ Res, 1998;83(5) :490- 500
8[5]Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K,Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species[J]. Hypertension,2001 ;37(6): 1450 - 7
9[6]Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranyllation 3 [J].J Leukoc Biol, 2001 ;69(6) :959 - 62
10[7]Su SF, Hsiao CL, Chu CW, Lee BC, Lee TM. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension [ J ]. Am J Cardiol, 2000; 86(5):514-8
